UEG Week 2023

New kids on the block - next generation therapeutics

Is IL-23 blockade breaking the ceiling in UC?

Do different JAKies have different profiles?

Anti-TL1A: on the way to precision medicine?

Benefit of JAKies in ulcerative colitis

The place of IL-23 blockers in crohn's disease

Key topic S1P-modulation

News on IBD therapy!

A lot of noise about IL-23 blockers - 1

Small molecules in IBD

A lot of noise about IL-23 blockers - 2

Guselkumab readily controls symptoms in patients affected by UC: results from the QUASAR study

Update on JAKies

Rapido controllo dei sintomi nei pazienti affetti da RCU in trattamento con Guselkumab: risultati dallo studio QUASAR

S1P-Modulatoren im Fokus

Update zu JAK-Inhibitoren

Novità nelle terapie per le IBD!

Small molecules nelle IBD

Viel Wirbel um die Interleukin-23-Blockade

Long-term efficacy of obefazimod in UC

Head-to-head efficacy comparison of risankizumab vs ustekinumab in CD refractory to anti-TNF: results from the sequence trial

First positive head-to-head trial in CD

Phase III results of filgotinib in CD

Risankizumab vs. ustekinumab in CD: The SEQUENCE trial

Ustekinumab vs. adamlimumab for prevention of early post-operative recurrence in CD

Mirikizumab reaches similar therapeutic outcomes in UC irrespective of prior exposure to advanced therapies.

High IL23 expression at baseline is predictive of clinical remission and endoscopic response in CD patients treated with risankizumab

Mirikizumab resulta efficace in RCU a prescindere dalla precedente esposizione a terapie avanzate.

Elevati livelli basali di IL23 predicono la remissione clinica e la risposta endoscopica in pazienti affetti da MDC trattati con Risankizumab

Ustekinumab vs. adalimumab για την πρόληψη της πρώιμης μετεγχειρητικής ενδοσκοπικής υποτροπής της νόσου του Crohn

Comparazione testa a testa di Risankizumab e Ustekinumab in pazienti refrattari a terapia con anti-TNF: risultati dallo studio sequence

PRA023 - a new anti-TL1A antibody in moderate to severe UC

Disease clearance induced by etrasimod and relationship between disease clearance and clinical outcome

Longterm endohistological response induced by mirikizumab in UC patients

Fast-acting etrasimod in UC

Another p19 antibody in UC

Mirikizumab in moderate to severe UC

Risankizumab in UC

Disease severity affects response in ozanimod treated pts.

Fase III resultaten met filgotinib in CD

PRA023 - un nuovo anticorpo anti-TL1A nella colite ulcerosa da moderata a grave

Lange termijn efficaciteit van Obefazimod UC

Mirikizumab nella colite ulcerosa da moderata a grave

The quest for perfect predictors of response - AI entering the stage

Can we stop biologics?

Efficacy and safety of switching iv vs. sc

How to prevent post-operative recurrence in CD?

Combined endpoints - composition and implementation in daily practice

S1P modulation: ozanimod vs. etrasimod

Navigating in the therapeutic IBD landscape

Infliximab sc application associated with better treatment persistence

More evidence that anti TNF-withdrawel increases relapse

To switch or not to switch in IBD - new real-life data already available

Navigeren in het therapeutisch landschap in IBD

Konwersja do terapii podskórnej NZJ - nowe dane typu real-life

Infliximab sc führt zu besseren Langzeitergebnissen

Postoperative recurrence in Crohn's disease after ileocecal resection - the PORCSE study

Medical news: Which treatment and when?

SEQUENCE study

Stopping adalimumab in early CD?

Surgical news: prevention of post-operative recurrence in crohn's disease

Did GETAID close the window of opportunity?

Nouveauté sur la chirurgie: Prévention de la récidive post-opératoire dans la maladie de Crohn

Actualités médicales: Quel traitement et quand?

Hat GETAID das "Window of opportunity" geschlossen?

Peut-on arrêter l'adalimumab dans la maladie de Crohn précoce?

SEQUENCE Studie

Nawroty pooperacyjne u pacjentów z chorobą Leśniowskiego-Crohna po resekcji ileocekalnej - badanie PORCSE

Which maintenance therapy in AS-CU is responding to steroids?

The anti TL1A/Dx-toolbox package: Are we entering precision medicine?

Quel traitement d'entretien dans l'AS-CU répondant aux stéroïdes?

Anti-TL1A im Paket mit der Dx-Toolbox - Einstieg in die Präzisionsmedizin?

Comprehensive disease control - a new currency

Comprehensive disease control - eine neue Währung

S1P modulation: effective and safe?

What do we know about multi-failures?

New safety signals on JAKies?

Is risankinumab effective for EIMs of IBD?

Do JAK inhibitors cause acne?

Effective control of EIMs in CD patients treated with risankizumab

Is it feasible to stop effective anti-TNF therapy in IBD? The GETECCU RCT

Czy możemy bezpiecznie przerwać skuteczną terapię anty-TNF w NZJ - wyniki badania grupy GETECCU

Προκαλούν οι αναστολείς των JAK ακμή;

Είναι το risankisumab αποτελεσματικό για τη θεραπεία των εξωεντερικών εκδηλώσεων των ΙΦΝΕ;

Efficace controllo delle MEI in pazienti affetti da MDC trattati con Risankizumab

Morphologic alteration of mesentric lymph nodes under ozanimod

Neutrophil fibroblast crosstalk is driving fribrosis in CD

Morphologische Veränderung mesenterialer Lymphknoten unter Ozanimod

Neutrophile Fibroblasteninteraktion treibt die Fibrose bei Morbus Crohn